Sharecare announces first quarter 2024 financial results and operational highlights ATLANTA – May 9, 2024 – Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced financial results for the quarter ended March 31, 2024. "As we report first quarter earnings, we are thrilled that our purpose-built digital navigation platform for Medicaid is launching on July 1, 2024, to approximately 750,000 Medicaid members," said Brent Layton, CEO of Share ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ FORM 10-K _____________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39535 SHARECARE, INC. ...

Conference Call Participants On today's call, we have Mr. Brent Layton, Chief Executive Officer, Mr. Justin Ferrero, President and Chief Financial Officer and Jeff Arnold, Executive Chairman, will join for the Q&A. Before we begin, we would like to remind you that certain statements made during this call will be forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, which includes statements regarding the strategic review, expecte ...

"In my first three months as CEO, I have been increasingly impressed by Sharecare's ability to innovate, and I believe that the breadth and depth of assets that the company has assembled over the years gives us everything we need to be successful," said Brent Layton, CEO of Sharecare. "In addition to the strength of our core business that serves self-insured employers and health plans as well as health systems and life sciences companies, I am particularly encouraged by the momentum we are experiencing in M ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ FORM 10-Q _____________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39535 (Exact name of regi ...

those clients and we're looking at ways that we could go at risk with them and manage certain percentages of their populations where we think our services could have impact. And so you'll see certain carve-outs coming from some of our clients in 2024 where we're going to go on the risk meaning that we're not going to charge the traditional PMPMs for some of these populations but have opportunities to get more of the upside based on our savings. And we're going to do that in a very measured approach. And so ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ FORM 10-Q _____________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR SHARECARE, INC. (Exact name of registrant as specified in its charter) Delaware 85-1365053 (State or other jurisdiction of incorporation or organization) 255 East Paces Ferry Road NE ...

Eric Percher Great. And my other question was on the life sciences business, and Jeff, you've obviously seen a few cycles. I'd love to get your view on the macro trend here and what enables you to put up a flat and a down market, and then Justin, understanding we're going to see a -- an increase in Q3, Q4 is typically that seasonally large quarter. How does this what you've seen year-to-date make you feel about Q4? Justin Ferrero So I can -- I'll start with that is that we're number one, as I talked about f ...

_____________________________________________ FORM 10-Q _____________________________________________ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 30305 Atlanta, Georgia (Address of Principal Executive Offices) (Zip Code) (404) 671-4000 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...

The combination of our advanced analytics, AI driven insights and proactive engagement through our advocates have significantly improved the quality of care we provide while maintaining cost efficiency. Further, our investment in sales is showing positive progress as we signed contracts totaling more than 275,000 new eligible lives in Q1, marking a significant increase from the same period last year. Company Participants David Larsen - BTIG Richard Close - Canaccord Genuity Eric Percher - Nephron Research O ...